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A deeper mechanistic understanding of tumour angiogenesis regulation is needed to improve
current anti-angiogenic therapies. Here we present evidence from systems-based miRNA
analyses of large-scale patient data sets along with in vitro and in vivo experiments that
miR-192 is a key regulator of angiogenesis. The potent anti-angiogenic effect of miR-192
stems from its ability to globally downregulate angiogenic pathways in cancer cells through
regulation of EGR1 and HOXB9. Low miR-192 expression in human tumours is predictive of
poor clinical outcome in several cancer types. Using 1,2-dioleoyl-sn-glycero-3-phosphati-
dylcholine (DOPC) nanoliposomes, we show that miR-192 delivery leads to inhibition of
tumour angiogenesis in multiple ovarian and renal tumour models, resulting in tumour
regression and growth inhibition. This anti-angiogenic and anti-tumour effect is more robust
than that observed with an anti-VEGF antibody. Collectively, these data identify miR-192 as a
central node in tumour angiogenesis and support the use of miR-192 in an anti-angiogenesis
therapy.
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A
ngiogenesis plays a central role in tumour progression.
However, targeting tumour vasculature has thus far
resulted in only modest improvement in progression-free
survival, with most patients still experiencing disease progression
despite an initial response1–3. Emerging pre-clinical and
clinical evidence indicates that upregulation of compensatory
pro-angiogenic signalling cascades contributes significantly
to the suboptimal therapeutic response in multiple cancer types,
including ovarian and renal cancer4–8. In patients with
glioblastoma, treatment with cediranib, a pan-VEGFR inhibitor,
also resulted in subsequent increases in FGF-2 and SDF-1 levels,
which can in turn contribute to tumour progression1,6. In a phase
II trial of FOLFIRIþB (folinic acid, fluorouracil, irinotecan
and bevacizumab) in colorectal cancer, significant increases in
several pro-angiogenic factors were also observed following the
treatment5. The identification of new anti-angiogenic approaches
that can overcome this compensatory mechanism are, therefore,
critical for improved therapeutic outcomes.
MicroRNAs (miRNAs) are endogenous small RNA molecules
that have the ability to target multiple genes concurrently9.
This unique property enables us to simultaneously target
multiple important pathways involved in angiogenesis. Pathway
redundancy is, thus, less likely to occur with such molecules.
Despite the promise, a systematic evaluation of miRNAs that
have a global impact on angiogenesis has not yet been reported.
To address this knowledge gap, we utilized a systems-based
approach integrating global miRNA profiling of highly and
poorly angiogenic tumours, large-scale patient data sets and
miRNA (microRNA)–mRNA (messenger RNA) correlation
analyses, to identify key miRNAs that are critical for regulating
tumour angiogenesis. This unbiased approach led us to identify
miR-192 as a key regulator of tumour angiogenesis. In both
highly angiogenic ovarian and renal cancer models, we show
that miR-192 significantly disrupts the crosstalk between tumour
and endothelial cells by targeting two key transcription factors,
EGR1 and HOXB9. This led to global downregulation of
pro-angiogenic factors. Delivery of miR-192 to tumours using
the 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) nano-
liposomal platform significantly inhibited tumour angiogenesis,
resulting in a much more profound anti-tumour effect compared
with that observed with murine anti-VEGF antibody (equivalent
to bevacizumab, a clinically approved anti-angiogenic agent).
Collectively, these findings provide an understanding of the
mechanisms by which miR-192 can regulate tumour angiogenesis
and supports its use as an effective therapeutic means of
inhibiting tumour angiogenesis.
Results
Effect of miR-192 on angiogenesis. To systematically identify
miRNAs that play critical roles in tumour angiogenesis,
integrative computational analyses were performed using
clinically annotated ovarian tumour samples to identify miRNAs
with low endogenous levels that correlate with (1) high
microvessel density (Fig. 1a), (2) high levels of angiogenic factors
and (3) poor clinical outcome (Fig. 1b). First, human high-grade
serous ovarian cancers (HGSC) were assessed for microvessel
density (MVD) by CD31 immunohistochemical staining
(n¼ 133, Fig. 1a). High-throughput miRNA profiling was
subsequently performed using Nanostring technology in 24
tumour samples with very high (436 vessels per high power field
(HPF), n¼ 12) or low (o16 vessels per HPF, n¼ 12) MVD
(Supplementary Data 1). All the 24 samples had o25% stromal
content, as confirmed by microscopic examination of the tumour
sections. For this study, we focused our efforts on identifying
miRNAs that are downregulated in tumours with high MVD.
From this analysis, 13 miRNAs were found to be decreased by
more than 80% (median miRNA expression) in highly angiogenic
tumours when compared with poorly angiogenic tumours. We
next examined the correlation between tumoral expression of
miRNAs and pro-angiogenic factors for these 13 miRNAs in The
Cancer Genome Atlas (TCGA) ovarian cancer data set (n¼ 559).
For each sample in TCGA data set, an angiogenesis score was
calculated based on the overall relative expression values for each
of the pro-angiogenic factors listed in Supplementary Data 2
(ref. 10). The correlation coefficient between angiogenesis
scores and miRNA expression was subsequently computed for
each miRNA (Fig. 1b). Among all the miRNAs examined,
miR-96, -192, -194 and -200b were found to display the strongest
negative correlations with pro-angiogenic factors (Po0.0001,
Supplementary Table 1). We next assessed the impact of these
four miRNAs on patient survival. High tumoral miR-192 and
miR-194 correlated with prolonged overall survival (OS; both
Po0.05). In contrast, tumoral miR-96 expression correlated with
poor OS, while no correlation was observed for miR-200b.
To study the roles of miR-192 and miR-194 in tumour
angiogenesis, we first examined the expression levels of these
miRNAs in endothelial cells isolated from human normal ovaries
or HGSCs. No statistically significant differences in miR-192 or
miR-194 expression were observed between normal versus
tumoral endothelial cells (Supplementary Fig. 1a). We thus
reasoned that the effect of these miRNAs on angiogenesis may
result from a paracrine effect from tumour cells. To test this
hypothesis, we introduced miRNA mimics into SKOV3ip1
ovarian cancer cells, which have low endogenous expression of
these two miRNAs (Supplementary Fig. 1b). RF-24, human
endothelial cells, were then exposed to conditioned media
obtained from control miRNA, miR-192 or miR-194-treated
SKOV3ip1 cells (48 h post transfection). Compared with control
miRNA treatment, miR-192 treatment resulted in 490%
reduction in endothelial tube formation (Fig. 1c), while only a
20% reduction was observed in the miR-194 treatment group
(Supplementary Fig. 1c). A similar result was also observed with
HeyA8 cells (Supplementary Fig. 1d). Consistent with these
findings, miR-192 transfection in SKOV3ip1 and HeyA8 cells
resulted in a significant downregulation of several important
angiogenic factors including IL6, IL8 and FGF2 levels (75, 80 and
50% decrease, respectively; Supplementary Fig. 1e), while only a
minimal downregulation of these factors was observed following
miR-194 treatment (Supplementary Fig. 1f). Incubation of the
RF24 cells with conditioned media collected from the SKOV3ip1
cells treated with miR-215, a miRNA closely associated with
miR-192, did not significantly inhibit tube formation,
demonstrating the unique ability of miR-192 to regulate tumour
angiogenesis (Supplementary Fig. 1g). Of note, direct expression
of miR-192 in RF-24 cells resulted in modest reduction in their
tube formation potential (Supplementary Fig. 1h). This indicates
that miR-192 mediates its anti-angiogenic effect mainly from its
effect on cancer cells. To further evaluate the impact of miR-192
on tumour angiogenesis, an in vivo matrigel plug assay was
next performed using conditioned media collected from the
SKOV3ip1 cells treated with control miRNA or miR-192.
Compared with VEGF (positive control) and conditioned media
obtained from control miRNA-treated cells, miR-192 treatment
led to substantial reductions in MVD and haemoglobin content
(58% decrease, Po0.05), a surrogate marker for functional blood
flow (Fig. 1d).
To further demonstrate the impact of miR-192 on angiogenesis
in clinical samples, an independent set of patient tumours
(n¼ 128) were used to assess the correlation between miR-192
and tumour MVD. Tumoral miR-192 expression levels showed
significant inverse correlation with blood vessel density, with a
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Figure 1 | Integrative analyses identified miR-192 as a key player in tumour angiogenesis. (a) MiRNA profiling in tumours with very high (436 vessels per
high power field (HPF), n¼ 12) or low (o16 vesselsper HPF, n¼ 12) microvessel density (MVD). MVD was assessed in high-grade serous ovarian cancers
(HGSC) using CD31 staining (n¼ 133). Representative images of tumours with high and low MVD are shown. (b) Correlation (Correl.) between the levels of
angiogenic (angio.) factors and expression of miRNAs that were downregulated in highly angiogenic tumours. Correlation analysis was performed using TCGA
ovarian cancer data set (n¼ 559, Spearman test). Angiogenesis scores were computed for each individual sample based on the overall relative expression of the
pro-angiogenic factors (Supplementary Data 2). The log-rank test was used to determine the association between miRNA expression and OS. (c) Tube formation
potential of RF24 cells following the exposure to conditioned media collected from SKOV3ip1 cells treated with control miRNA or miR-192 (48h post transfection).
Tube formation potential was assessed 6 h post incubation (n¼ 5, Student’s t-test). (d) Representative images (left) and haemoglobin quantification (right) of the
in vivo matrigel plug assay (n¼ 3, Student’s t-test, 7 days post injection). Matrigel was mixed with VEGF alone (positive control) or conditioned media collected
from SKOV3ip1 cells treated with control miRNA or miR-192. (e) Correlation between miR-192 expression levels and MVD (Student’s t-test) or OS (log-rank test)
in an independent cohort of human ovarian tumours (n¼ 128). MVD was quantified via CD34 staining. (f) A flow-chart describing methods used for identifying
important anti-angiogenic miRNAs. Scale bar, 100mm. Bars and error bars represent mean values and the corresponding SEMs (*Po0.05; ****Po0.0001).
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68% reduction in MVD in tumours with high levels of
miR-192 compared with those with low tumoral levels of
miR-192 (percentile cutoff¼ 0.33, Po0.0001, Fig. 1e). In this
patient cohort, low tumoral miR-192 expression was also found
to be significantly associated with worse OS (3.86 versus 6.85
years, log-rank P¼ 0.001, Supplementary Table 2), consistent
with the results from TCGA ovarian data set. Importantly,
tumoral miR-192 expression remained an independent predictor
of survival following the multivariate analysis accounting for
age, stage, grade and extent of cytoreduction (Po0.001, Cox
proportional-hazards model). Our systematic analyses thus
identified miR-192 as a key player in tumour angiogenesis
(Fig. 1f). Indeed, pathway analysis of genes that are negatively
associated with miR-192 expression in TCGA ovarian data
set also revealed angiogenesis as one of the major pathways
affected by this miRNA (Supplementary Table 3).
MiR-192 mediates global downregulation of angiogenic factors.
To identify the dominant angiogenic factors regulated by miR-192,
we first examined the correlation between miR-192 and mRNA
level of 65 angiogenic factors in TCGA ovarian cancer data set
(Supplementary Data 2). PTGIS and IL6 were among the top
molecules identified to have the strongest negative correlation with
tumoral miR-192 expression (levels increased by 84%, P¼ 2.32
 10 8 and 43%, P¼ 0.018 in tumours with low miR-192
compared with the ones with high miR-192, respectively; miR-192
percentile cutoff of 0.26 was used for defining high versus low
expression). In contrast to PTGIS where the level was not altered
following miR-192 transfection, the cells treated with miR-192
displayed significantly lower IL6 mRNA levels compared with the
cells treated with control miRNA (45–95% reduction,
Supplementary Figs 1e and 2a). However, a luciferase assay using
the entire 30-untranslated region (30-UTR) of IL6 revealed the lack
of direct binding of miR-192 to IL6 (Supplementary Fig. 2b).
To systematically examine the molecular mechanisms by which
miR-192 mediates its anti-angiogenic effect, a microarray was
performed following miR-192 transfection in the SKOV3ip1 cells
(Supplementary Data 3). Zinc Finger E-Box Binding Homeobox 2
(ZEB2), a known miR-192 target11, was used as a positive control
for this experiment (Supplementary Fig. 2c). Pathway enrichment
analysis using Netwalker12 showed that miR-192 significantly
alters the angiogenesis pathway (P¼ 7.8 10 6, Supplementary
Data 4) and 6 out of the 15 most significantly downregulated
genes are pro-angiogenic (Fig. 2a). Further examination of all
pro-angiogenic factors that have log2 expression levels above 8
(control miRNA-treated cells) in the microarray data set revealed
the ability of miR-192 to globally downregulate angiogenic
pathways (Fig. 2b). We subsequently hypothesized that miR-192
mediates its global anti-angiogenic effect by targeting
transcription factors that regulate multiple angiogenic
molecules. Using the list of pro-angiogenic molecules shown in
Fig. 2b, transcription factor analysis was performed using
Genomatix software at a stringent matrix similarity score cutoff
of 0.9. A total of 158 transcription factors were predicted to
regulate more than five angiogenic factors with 13 of them
predicted to be direct targets of miR-192 by at least four miRNA
target prediction algorithms (Supplementary Table 4 and Fig. 2c).
We next assessed the ability of miR-192 to target these
transcription factors in SKOV3ip1 cells. The levels of ZBTB7,
PLAG1 and TAL1-E2A were not examined due to their low
expression levels in SKOV3ip1 cells. At 48 h following miR-192
transfection, EGR1 and HOXB9 mRNA levels were the most
downregulated by approximately 75% (Fig. 2d). The
downregulation of EGR1 and HOXB9 by miR-192 was further
confirmed in another ovarian cancer cell line, HeyA8
(Supplementary Fig. 2d). The EGR1 and HOXB9 protein levels
were also both significantly downregulated following miR-192
transfection in both the cell lines examined (Supplementary
Fig. 2e). Using the data set described in Supplementary Table 2,
we further assessed the correlation between miR-192 and EGR1
or HOXB9 protein expression levels in human ovarian epithelial
tumours. Tumoral miR-192 expression levels showed significant
inverse correlations with EGR1 (Po0.001) and HOXB9
(Po0.05) protein expression (n¼ 98, Supplementary Fig. 2f).
Their expression in tumours also correlated with poor overall
survival (Supplementary Fig. 2g). To assess whether EGR1 and
HOXB9 are direct targets of miR-192, luciferase assays using the
entire 30-UTR were performed. As compared with cells
transfected with control miRNA, the relative luciferase activity
for EGR1 and HOXB9 were both significantly reduced by miR-
192 (Fig. 2e). For both genes, mutation of the predicted binding
site (Supplementary Fig. 2h) abrogated knockdown, indicating
that EGR1 and HOXB9 are both direct miR-192 targets.
We next examined the effect of EGR1 and HOXB9 on
angiogenesis. Tube formation assays were performed using
RF24 cells exposed to conditioned media collected from either
SKOV3ip1 (Fig. 2f) or HeyA8 cells (Supplementary Fig. 2i)
following silencing of EGR1 and/or HOXB9. Compared with
control short interfering RNA (siRNA), EGR1 silencing in the
SKOV3ip1 cells resulted in 40% decrease in tube formation
potential. Silencing of EGR1 using another siRNA sequence in
HeyA8 cells also produced a similar effect (Supplementary
Fig. 2i). Exposing RF24 cells to conditioned media collected
from HOXB9 silenced cells also reduced their tube formation
potential irrespective of the cell line or siRNA sequence used
(Fig. 2f and Supplementary Fig. 2i). Silencing both EGR1 and
HOXB9 resulted in a further reduction of tube formation
potential (Fig. 2f, Po0.01 or Po0.0001, compared with siEGR1
or siHOXB9 treatment alone, respectively). This effect was not
fully rescued by replacing IL6 and IL8, two cytokines that are
most downregulated by miR-192 treatment, in the conditioned
media (Supplementary Fig. 2j). Importantly, we further showed
that the observed decrease in tube formation potential upon
EGR1 or HOXB9 silencing in these cells is not a result of
decreased cell viability (Supplementary Fig. 2k).
To investigate whether the decrease in angiogenic potential
upon EGR1 or HOXB9 silencing is a result of the decreased
production of pro-angiogenic cytokines, we examined mRNA
levels of pro-angiogenic factors that are predicted to be directly
regulated by EGR1 or HOXB9. EGR1 silencing in the SKOV3ip1
cells resulted in significant downregulation of IL6, IL8, CXCL1,
EFNA1 and FGF2 whereas HOXB9 silencing mediated
downregulation of HIF1a, IL1b and ITGA6 (Fig. 2g). Notably,
EGR1 and HOXB9 were both regulated by miR-192 but had
different downstream targets. Similar effects were observed in
HeyA8 cells (Supplementary Fig. 2l). We further showed, via
chromatin immunoprecipitation (ChIP) assays, that EGR1 and
HOXB9 can directly bind to the promoter regions of IL6 and
EFNA1 (EGR1) and IL1b and ITGA6 (HOXB9; Supplementary
Fig. 2m). Next, EGR1 and HOXB9 constructs which lack the
30-UTR component were used to generate cells that are insensitive
to miR-192 treatment. Importantly, restoring EGR1 abrogated
the miR-192 induced downregulation of EFNA1 and CXCL1.
In contrast, expression of both EGR1 and HOXB9 was necessary
to completely abrogate the effects of miR-192 on IL6, IL8, and
IL1b levels, with a rebound effect observed with IL1b (Fig. 3a).
This rescue of pro-angiogenic factor expression in EGR1 and/or
HOXB9 expressing cells resulted in significant abrogation of the
anti-angiogenic effects of miR-192. In contrast to empty lentiviral
vector (EV)-transduced SKOV3ip1 cells where miR-192
treatment resulted in a 60% reduction in tube formation
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Figure 2 | The anti-angiogenic effect of miR-192. (a) Top 15 molecules downregulated by miR-192. Whole-genome microarray was performed at 48 h post
transfection in SKOV3ip1 cells (n¼ 3). (b) The effect of miR-192 on pro-angiogenic factors. (c) Transcription factors predicted to regulate 45 angiogenic
factors and are potential direct targets of miR-192. The lines indicate potential interactions between the transcription factors and the pro-angiogenic genes.
(d) The effect of miR-192 on the levels of transcription factors that can potentially mediate the broad anti-angiogenic function of miR-192. The mRNA levels
of each transcription factor was assessed at 24 h post transfection in SKOV3ip1 cells (n¼ 3, Student’s t-test). (e) Relative (Rel.) luciferase activity
normalized to empty control for EGR1 or HOXB9 30-untranslated region (UTR). Mutated constructs have predicted miR-192 binding site deleted. SKOV3ip1
cells were transfected with miR-192 and UTR luciferase constructs using FuGene transfecting reagent, and luciferase assay was performed at 24 h post
transfection (n¼4, Student’s t-test). (f) Tube formation potential was assessed in RF24 cells after exposing to conditioned media collected from SKOV3ip1
cells treated with siEGR1 and/or siHOXB9 (48 h post transfection, n¼ 5, Student’s t-test). (g) Effect of EGR1 or HOXB9 silencing on levels of angiogenic
factors. SKOV3ip1 cells were treated with siRNAs and RNA was isolated at 48 h post transfection (n¼ 3, Student’s t-test). Scale bar, 100mm. All bars and
error bars represent mean values and the corresponding s.e.m. (*Po0.05; **Po0.01; ***Po0.001; and ****Po0.0001).
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potential, only 30 and 20% downregulation in tube formation
potential was achieved using conditioned media collected from
EGR1- and HOXB9-expressing SKOV3ip1 cells following
miR-192 treatment, respectively (Fig. 3b). Dual EGR1 and
HOXB9 expression resulted in complete rescue of the anti-
angiogenic effect of miR-192. Similar findings were also observed
in HeyA8 cells (Supplementary Fig. 3). These results indicate that
EGR1 and HOXB9 are necessary and sufficient to account for the
anti-angiogenic effects of this miRNA.
Upstream regulation of miR-192. Next, we investigated the
potential mechanism by which miR-192 is downregulated in
tumours. We first correlated miR-192 expression with copy
number alteration and promoter methylation in each of the
TCGA data sets (21 cancer types). No significant correlation was
noted between copy number and expression. However, we
observed strong negative correlations between methylation levels
of four probes, which target miR-192 directly and overall
miR-192 expression levels in multiple cancer types
(Supplementary Table 5). Correlation in ovarian cancer was not
assessed here as insufficient number of ovarian cancer samples
had methylation 450 data available. As an alternative, to assess
whether miR-192 expression is indeed regulated by methylation
in ovarian cancer, we treated the SKOV3ip1 cells with azacitidine,
a methylation inhibitor. Unexpectedly, no rescue of miR-192
level was observed following the azacitidine treatment in the
SKOV3ip1 cells (Supplementary Fig. 4a), despite successful
demethylation of the miR-192 promoter region (Supplementary
Fig. 4b). Minimal rescue of miR-192 levels was observed follow-
ing the azacitidine treatment in HeyA8 cells (Supplementary
Fig. 4a,b).
To examine other potential regulators of miR-192, we used
Genomatix software to predict potential transcription factors
that can bind to the miR-192 promoter region. Eighty-three
potential candidates were identified using a stringent matrix
similarity score cutoff of 0.95. Of these genes, ZEB1, ETV1 and
TWIST1 were found to have significant correlations with
miR-192 expression in TCGA ovarian database (n¼ 559,
Po0.0001). Upon examining expression levels of these genes
and miR-192 in the NCI-60 cell line database13, we found
TWIST1 to have the most significant negative correlation with
miR-192 expression (Supplementary Fig. 4c). We, thus,
hypothesized that TWIST1, a transcription factor commonly
upregulated in hypoxia, can act as a transcriptional repressor for
miR-192. Indeed, when we introduced TWIST1 into both
SKOV3ip1 and HeyA8 cells, miR-192 levels were significantly
decreased (Supplementary Fig. 4d). The ability of TWIST1 to
bind to the promoter region of miR-192 was further assessed
using a ChIP assay with an anti-TWIST1 antibody. Significant
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Figure 3 | MiR-192 mediates its anti-angiogenic effects through regulating EGR1 and HOXB9. (a) SKOV3ip1 cells stably expressing empty vector (EV),
EGR1, HOXB9 or EGR1þHOXB9, were treated with control miRNA or miR-192. Expression levels of pro-angiogenic factors downstream of EGR1 (EFNA1,
CXCL1, FGF2) or downstream of both EGR1 and HOXB9 (IL-6, IL-8 and IL-1b) were assessed at 48 h following transfection (n¼ 3, Student’s t-test). (b) Tube
formation potential of RF-24 cells was assessed following incubation with conditioned media collected from SKOV3-EV, EGR1, HOXB9 and EGR1þHOXB9
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fold enrichment in the binding of TWIST1 to the miR-192
promoter region was observed compared with the IgG
control (Supplementary Fig. 4e, Po0.01). These results
indicate the potential role of TWIST1 in regulating miR-192 in
ovarian tumours. Given the role of TWIST1 in regulating
epithelial–mesenchymal transition, we further assessed whether
there is a relationship between miR-192 level and epithelial
morphology of ovarian tumours. We examined miR-192
expression in mesenchymal versus epithelial subtypes of ovarian
tumours using TCGA ovarian data set14. We found that TWIST1
is expressed at a much higher level in the mesenchymal group
when compared with the epithelial group (Supplementary Fig. 4f,
P¼ 2.2e 16). In contrast, miR-192 was expressed at a
significantly lower level in the mesenchymal group (P¼ 0.02),
but the difference in expression between the epithelial and
mesenchymal groups was marginal. This indicates that changes in
epithelial–mesenchymal transition phenotype may not be the
main function of this miRNA. We, thus, reasoned that while
TWIST1 and miR-192 are closely linked with each other, the
survival benefit that we observed with miR-192 is not purely a
reflection of the difference in TWIST1 expression.
In vivo effects of miR-192 on ovarian cancer progression. Given
the anti-angiogenic property of miR-192, we next examined the
effect of miR-192 on tumour progression in orthotopic
mouse models of ovarian cancer. We first introduced lentiviral
vectors expressing control miRNA (SKOV3ip1-NC) or miR-192
(SKOV3ip1-miR-192) into SKOV3ip1 cells. Compared with
SKOV3ip1-NC cells, SKOV3ip1-miR-192 cells exhibit a
significant increase in miR-192 level (Supplementary Fig. 5a).
Similar to the SKOV3ip1 cells treated with miR-192 mimics
(Supplementary Fig. 1d), the RF24 cells treated with conditioned
media collected from SKOV3ip1-miR-192 cells showed
significantly reduced tube formation potential compared with
that of SKOV3ip1-NC cells (Supplementary Fig. 5b). We
subsequently injected SKOV3ip1-NC or SKOV3ip1-miR-192
cells into the peritoneal cavity of athymic nude mice (n¼ 10 per
group). Tumour burden was assessed 4 weeks following the cell
injection. Mice bearing SKOV3ip1-miR-192 tumours showed a
70% decrease in tumour burden (Po0.05, Fig. 4a) compared with
mice in the SKOV3ip1-NC group. The number of tumour
nodules was also decreased in mice bearing miR-192-expressing
tumours (Supplementary Fig. 5c). Compared with SKOV3ip1-NC
tumours, SKOV3ip1-miR-192 tumours showed a significant 55%
reduction in MVD (Po0.05), with a 50% increase in the
percentage of blood vessels covered with pericytes (Po0.05,
Fig. 4b). This further corroborates the paracrine effect of tumoral
miR-192 expression on blood vessel maturation. Notably, stable
transduction of SKOV3ip1 with miR-192 had no effect on
the growth rate compared with cells transduced with control
miRNA in vitro (Supplementary Fig. 5d). These findings further
point to the role of tumour microenvironment in mediating the
anti-tumour effects of miR-192.
Having established the anti-tumour effect of miR-192 in vivo,
we next tested the feasibility of using miR-192 therapeutically to
treat ovarian cancer. MiRNAs were delivered via intraperitoneal
injection twice weekly using a well-characterized nanoparticle
platform, neutral DOPC nanoliposomes15–17. The SKOV3ip1
cells were injected into the peritoneal cavity of mice (n¼ 10
per group). There were two treatment groups: (1) non-targeting
control (NC) miRNA-DOPC or (2) miR-192-DOPC. After 4
weeks of therapy, the animals were killed and necropsies
were performed. Significant decreases in tumour weight
(85%, Po0.01), number of tumour nodules (80%, Po0.01)
and volume of ascites (95%, Po0.05) were observed following
miR-192-DOPC treatment when compared with mice treated
with NC miRNA-DOPC (Fig. 4c, Supplementary Fig. 5e).
No group showed decreased body weight, a major indicator of
toxicity (Supplementary Fig. 5f). Moreover, histopathological
examination of major organs following 4 weeks of miR-192-
DOPC therapy revealed no abnormalities (Fig. 4d). Importantly,
significant reductions in EGR1 and HOXB9 levels were observed
in tumours following two doses of miR-192-DOPC treatments,
compared with tumours treated with control miRNA-DOPC
(Fig. 4e). Next, a survival experiment was carried out to assess the
impact of miR-192 on survival in mice (n¼ 7). Mice bearing
SKOV3ip1 tumours were treated with control miR or miR-192
containing DOPC nanoliposomes. The mice were killed
individually once they became moribund, and a Kaplan–Meier
curve was used to analyse the survival difference between the
different treatment groups. We showed that miR-192 significantly
enhanced survival (P¼ 0.009, Supplementary Fig. 5g).
Given the ability of miR-192 to modulate tumour angiogenesis,
we next assessed the feasibility of treating ovarian tumours with
combined therapy of miR-192 and topotecan, a chemotherapeutic
agent with anti-angiogenic activity18. The mice were treated
with miRNAs-DOPC twice weekly as described above and
topotecan was administered once weekly (intravenously,
5mg kg 1) starting 7 days after tumour cell implantation. The
mice were killed after 4 weeks of therapy. Similar to the
results obtained previously, miR-192-DOPC treatment reduced
the tumour burden by approximately 85% (SKOV3ip1 model,
Supplementary Fig. 5h). Compared with NC miRNA-DOPC
alone, the mice treated with topotecan and NC miRNA-DOPC
resulted in a 50% reduction in tumour burden. Combination
treatment of miR-192 and topotecan resulted in a 40% further
reduction in tumour weight compared with mice treated with
NC miRNA-DOPC plus topotecan. We next sought to compare
the anti-angiogenic and anti-tumour effect between miR-192
and murine anti-VEGF antibody, B20-4.1.1 (equivalent to
bevacizumab, a clinically used anti-VEGF agent for the
treatment of multiple cancer types). OVCA-432 high-grade
serous ovarian cancer cells were injected into the peritoneal
cavity of mice (n¼ 10 per group) and all the treatments started
after tumours had been established (3 weeks following the tumour
cell injection). There were four treatment groups: (1) Phosphate-
buffered saline (PBS), (2) B20-4.1.1, (3) NC miRNA-DOPC and
(4) miR-192-DOPC. All the mice were killed after 3 weeks of
therapy. As expected, B20-4.1.1 treatment resulted in a significant
reduction in tumour burden (60% reduction compared with PBS
treatment, Po0.01, Fig. 4f). Notably, miR-192-DOPC therapy
induced an even more profound tumour regression effect,
resulting in 490% reduction in tumour weight compared with
PBS treatment (Po0.0001). As miR-192 expression has been
previously reported to be associated with VEGF levels19, we
assessed both miR-192 and miR-194 levels in tumours treated
with B20. As expected, there was a modest increase in miR-192
level in B20-treated tumours when compared with the PBS
control group, although the difference was not statistically
significant (Supplementary Fig. 5i). This degree of increase in
miR-192 level was significantly lower than that observed from
miR-192-DOPC treatment (Supplementary Fig. 5j). Importantly,
miR-192-DOPC treatment resulted in significant reduction in
blood vessel density as well as increased pericyte coverage of
residual blood vessels (Supplementary Fig. 5k). We showed that
the ability of miR-192 to reduce blood vessel density was more
profound than that observed with the B20 treatment.
Importantly, B20 treatment did not affect the percentage of
pericyte coverage of residual blood vessels. We further showed
that miR-192-DOPC treatment resulted in a significant increase
in the number of apoptotic cells in tumours (Po0.001,
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Figure 4 | Anti-angiogenic and therapeutic effects of miR-192 in orthotopic mouse models of ovarian cancer. (a) Aggregate mass of intraperitoneal
implanted SKOV3ip1-NC and SKOV3ip1-miR192 tumours (n¼ 10, Student’s t-test). (b) Effect of miR-192 expression on MVD and vessel pericyte coverage
in SKOV3ip1 tumours (n¼ 5, Student’s t-test). Higher magnification images are shown in the insets. (c) Effect of miR-192-DOPC treatment on tumour
weight in SKOV3ip1 tumour-bearing mice (n¼ 10, Student’s t-test). (d) Histopathological examination of major organs following 4 weeks of control
miRNA-DOPC or miR-192-DOPC therapy (n¼ 3). (e) Tumoral EGR1 and HOXB9 levels following two doses of control miRNA-DOPC or miR-192-DOPC
therapies in SKOV3ip1 tumours (n¼ 5, Student’s t-test). (f) The effects of B20, control miRNA-DOPC or miR-192-DOPC on tumour burden in mice bearing
OVCA-432 tumours (n¼ 10, student t-test). (g) The impact of miR-192-DOPC on tumour burden in orthotopic SKOV3-EV, EGR1, HOXB9 and
EGR1þHOXB9 tumours (left, n¼ 10, Student’s t-test). Representative images are shown (right; white circles: tumours). (h) Representative images of CD31
(red), desmin (green) and nuclei visualized with Hoechst 33342 (blue) in SKOV3ip1-EV and EGR1þHOXB9 tumours. Higher magnification images are
shown in the insets. Bar graphs (right) show the quantitative analyses of CD31 and desmin staining (n¼ 5, Student’s t-test). Bars and error bars represent
mean values and the corresponding s.e.m. (*Po0.05; **Po0.01; ***Po0.001; and ****Po0.0001).
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Supplementary Fig. 5l). Collectively, these results indicate that
significant therapeutic benefit can be derived from miR-192-
mediated inhibition of multiple pro-angiogenic pathways
simultaneously.
We next assessed whether the anti-angiogenic effect of
miR-192 can be abrogated by EGR1 and/or HOXB9 expression
in SKOV3ip1 tumours. EGR1 and HOXB9 constructs that lack
the 30-UTR component were used to generate cells that are
insensitive to miR-192 treatment. SKOV3ip1-empty vector (EV),
SKOV3ip1-EGR1, SKOV3ip1-HOXB9 and SKOV3ip1-EGR1þ
HOXB9 cells were injected into the peritoneal cavity of mice.
The mice were then treated with control miRNA-DOPC or
miR-192-DOPC twice weekly for 4 weeks. In contrast to the
SKOV3ip1-EV tumours where miR-192 treatment resulted in a
90% reduction in tumour burden, only 65 and 30% reduction in
tumour burden was observed for tumours expressing EGR1 and
HOXB9, respectively (Fig. 4g). The expression of both EGR1 and
HOXB9 in tumours completely abrogated the anti-tumour effect
of miR-192. Only minimal decreases in MVD and increases in the
extent of pericyte coverage of residual blood vessels were observed
in tumours expressing both EGR1 and HOXB9 after the miR-192
treatments (Fig. 4h), emphasizing the key roles EGR1 and HOXB9
play in mediating the anti-angiogenic effects of miR-192. We
further confirmed that while EGR1 and HOXB9 expression
decreased the extent of pericyte coverage around the blood
vessels, their expression has minimal effect on desmin levels in
pericytes or pericyte-like cells (Fig. 4h and Supplementary
Fig. 5m). Importantly, in SKOV3ip1-EV tumours, tumour
vasculature following the miR-192 treatment was significantly
less permeable than the control miRNA group (Supplementary
Fig. 5n). In contrast, minimal difference in vessel permeability
was observed between SKOV3ip1-EGR1þHOXB9 tumours
treated with control miRNA and miR-192.
Effects of miR-192 on angiogenesis in renal cancer. To assess
whether miR-192 can also affect tumour angiogenesis in other
cancer types, we examined the level of miR-192 in tumours across
19 cancer types using TCGA data sets (Supplementary Fig. 6a).
Since clear-cell renal carcinomas are highly angiogenic20, and anti-
angiogenic agents are the mainstay of treatment for kidney cancer,
we hypothesized that miR-192 treatment may show therapeutic
benefit in renal cancer patients with low endogenous tumoral
miR-192 expression. Indeed, renal cancers were found to have a
large dynamic range of miR-192 expression (Supplementary
Fig. 6a), and patients with tumours expressing low levels of
miR-192 had significantly worse OS (median OS of 69 versus 147
months for tumours with low versus high miR-192 expression,
respectively, Po0.005; percentile cutoff¼ 0.29; Fig. 5a).
We introduced miR-192 mimics into two renal cancer cell
lines, RCC4 and A498. Similar to ovarian cancer, miR-192
treatment mediated a robust downregulation of EGR1 and
HOXB9 levels (Fig. 5b) and significant decreases in several
angiogenic factors including IL6, IL8 and EFNA1 (Fig. 5c);
consistent with the pattern observed after siEGR1/siHOXB9
treatment (Supplementary Fig. 6b,c). Exposing the RF24 cells to
conditioned media collected from RCC4 or A498 cells treated
with miR-192 resulted in 50–70% decrease in tube formation
potential when compared with control miRNA treatment
(Fig. 5d, Supplementary Fig. 6d). This miR-192-mediated anti-
angiogenic effect was significantly reduced following the rescue of
EGR1 and/or HOXB9 levels by lentiviral transduction in these
renal cancer cells (Fig. 5c,d, Supplementary Fig. 6d).
To assess the therapeutic effect of miR-192 in renal cancer, we
injected A498 renal cancer cells expressing an EV or both EGR1
and HOXB9 (A498-EV and A498-EGR1þHOXB9, respectively)
into the subcapsular space in the kidneys of mice. All the cells
were luciferase-labelled to enable the assessment of tumour
burden. Starting 7 days following the cell implantation, the mice
were treated with DOPC nanoliposome-delivered control miRNA
or miR-192 twice a week. MiR-192 treatment resulted in a495%
decrease in tumour burden in mice bearing A498-EV tumours
(Fig. 5e). In contrast, the tumours expressing EGR1 and
HOXB9 proteins failed to respond to miR-192 therapy, again
demonstrating the central role of these two proteins in miR-192-
mediated anti-tumour effect. Collectively, both the in vitro and
in vivo results shown here were consistent with those observed in
ovarian cancer models, indicating the broad implications of
modulating miR-192 in different cancer types.
Discussion
Using an integration of systems-based bioinformatics coupled
with experimental models, we rigorously document here the
central role of miR-192 in regulating tumour angiogenesis. To
date, no other miRNA has been identified to have such a global
effect on angiogenesis. We demonstrated that the potent
anti-angiogenic effect of miR-192 stems from its ability to
globally downregulate angiogenic pathways in cancer cells
through regulating two key transcription factors, EGR1 and
HOXB9 (Fig. 6). Using the DOPC nanoliposomal platform, which
is currently being tested in clinical trials, we showed that miR-192
can mediate potent anti-angiogenic and anti-tumour effects in
multiple orthotopic mouse models of ovarian and renal cancer.
The anti-angiogenic and anti-tumour effects of miR-192
were found to be much more robust than that achieved with
anti-VEGF antibody. As upregulation of the compensatory
pro-angiogenic signalling cascades has been shown to play a
crucial role in resistance to anti-angiogenic therapy, our finding
of the global anti-angiogenic effect of miR-192 represents a
promising new approach for targeting tumour angiogenesis.
Although the downregulation of miR-192 has been previously
observed in multiple cancer types21–25, its clinical relevance and
the feasibility of using it as a therapeutic agent are currently
unknown. Here, using large-scale patient data sets, we
demonstrated that decreased tumoral miR-192 levels are
associated with increased angiogenesis and poor overall survival
in patients with high-grade serous ovarian or renal clear cell
carcinomas. We further presented several lines of pre-clinical
evidence demonstrating the marked therapeutic potential of miR-
192 in ovarian and renal cancer models without causing toxicity
in normal organs. To date, the biological function of miR-192 has
been reported predominantly in the areas of cell survival26 and
metastasis through direct targeting of MDM2, TYMS, SIP1 or
ZEB2 (refs 21,24,27–29). While its effect on these genes could
contribute partially to its anti-tumour activity, recent studies that
used systematic translational approaches to identify key
microRNAs important for metastasis did not identify miR-192
to be the top regulator for cancer metastasis30–32. In contrast, the
miR-200 family, which has been reported to play key roles in
angiogenesis16 and metastasis33, was identified in both our
angiogenesis-specific analysis as well as the metastasis focused
analysis reported by Mudduluru et al.30 The investigation of the
specific role of miR-192 in regulating tumour angiogenesis is thus
warranted. Previous reports have documented the ability of
miR-192 to negatively regulate factors such as VEGFA34 or
ICAM1 (ref. 35) leading to inhibition of metastatic colonization of
tumour cells. However, the mechanism by which this miRNA
mediates its broad anti-angiogenic effect was not established. We
report here that EGR1 and HOXB9 transcription factors are
responsible for mediating the broad anti-angiogenic function of
miR-192, since restoration of EGR1 and HOXB9 completely
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rescued this effect. Importantly, we showed that miR-192 is able
to mediate profound anti-angiogenic and anti-tumour effects
in vivo, independent of its impact on cancer cell growth.
The central role of EGR1 and HOXB9 in tumour angiogenesis
has recently been recognized. For instance, EGR1 was shown to
be important in mediating angiopoietin-1-induced endothelial
cell proliferation, migration and differentiation36. Both these
transcription factors have been reported to bind directly to the
promoter regions of several angiogenic factors, such as IL8,
VEGF and FGF2, resulting in increased production of these
cytokines37–41. Through integrative analyses in this study, we
uncovered the new roles of EGR1 and HOXB9 in regulating other
important angiogenic factors, including CXCL1, EFNA, IL6 and
IL1b. Importantly, EGR1 and HOXB9 have both been shown to
correlate with poor patient survival in multiple cancer types42–46.
The identification of miR-192 as a common upstream regulator of
these two key transcription factors is thus of high importance
given that to date, mechanisms of EGR1 and HOXB9 regulation
are still largely unknown and no effective therapeutic means has
been developed to regulate their expression.
Given the ability of miR-192 to globally downregulate the
angiogenic pathways, it provides a central node to potently block
tumour angiogenesis. The ovarian and renal cancers are both
highly angiogenic cancer types, with high miR-192 levels
correlating with significantly improved patient survival. As such,
it is anticipated that patients whose tumours have low miR-192
expression would greatly benefit from miR-192 therapy.
Collectively, our data provide an important advance in
understanding the importance and mechanism of miR-192 in
regulating tumour angiogenesis. Our complete understanding of
this mechanistic pathway will open rational avenues for
therapeutic interventions and novel combination therapies for
cancer patients.
Methods
Cell lines and cell growth assays. All ovarian cancer cell lines (SKOV3ip1,
HeyA8, OVCAR-8, OVCA-432) were maintained in RPMI 1640 media
supplemented with 15% fetal bovine serum (FBS) and 0.1% gentamicin sulfate
(GeminibBioproducts, Calabases, CA, USA; refs 47,48). The A498 and RCC4 cell
lines were kindly provided by Dr Eric Jonasch (M.D. Anderson Cancer Center) and
were maintained in DMEM-high glucose supplemented with 10% FBS and 0.1%
gentamicin. The RF24 cells were maintained in MEM supplemented with 10% FBS,
sodium pyruvate, MEM vitamins, L-glutamine, and MEM non-essential amino
acids. 10T1/2 pericyte-like cells were maintained in DMEM-high glucose
supplemented with 10% FBS and 0.1% gentamicin. All the cell lines were routinely
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Figure 5 | The anti-angiogenic and antitumour effects of miR-192 in renal tumours. (a) Kaplan–Meier plot for OS based on tumoral miR-192 expression
for patients with renal tumours in TCGA KIRC data set (n¼413, log-rank test). (b) EGR1 and HOXB9 levels in RCC4 and A498 cells at 24 h following control
miRNA or miR-192 treatment (n¼ 3, Student’s t-test). (c) The effect of miR-192 on levels of key angiogenic factors in A498-EV and A498-EGR1þHOXB9
cells (n¼ 3, Student’s t-test). IL6, IL8 and EFNA1 are among the angiogenic factors that are most significantly downregulated by miR-192 in A498 cells.
(d) Tube formation potential of RF24 cells following incubation with conditioned media collected from control miRNA or miR-192 treated A498-EV or
A498-EGR1þHOXB9 cells. Bar graph (right) shows the quantitative analyses of number of nodes per HPF (n¼ 5, Student’s t-test). (e) The effect of
miR-192 on tumour burden in mice bearing luciferase-labelled A498-EV or A498-EGR1þHOXB9 tumours. The graph (left) shows quantitative assessment
of the total absolute luciferase signal (photons s 1 cm 2 sr 1, n¼ 10, student t-test). Representative images from each treatment group are shown (right).
Scale bar, 100mm. All bars and error bars represent mean values and the corresponding SEMs. (*Po0.05; **Po0.01; ***Po0.001; and ****Po0.0001).
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tested to confirm the absence of Mycoplasma. Cell lines were validated by Short
Tandem Repeat (STR) DNA fingerprinting using the Promega 16 High Sensitivity
STR Kit. The STR profiles were compared with online search databases
(DSMZ/ATCC/JCRB/RIKEN) of 2,455 known profiles; along with the MD
Anderson Characterized Cell Line Core database of 2,556 known profiles. The STR
profiles matched known DNA fingerprints or were unique. All the in vitro
experiments were conducted with 60–80% confluent cultures. For cell growth
assays, the cells were plated in six-well plates in triplicate and were counted each
day for 6 days using a Beckman Coulter cell counter.
TCGA data exploratory analyses. We used clinically annotated data from TCGA
obtained from the Open-Access and Controlled-Access tiers of the TCGA Data
Portal (http://tcga-data.nci.nih.gov/tcga/findArchives.htm) with NIH approval.
The expression data for all the miRNAs were obtained from Agilent miRNA
microarrays and Illumina miRNA-Seq data sets. For the miRNA-Seq data, we
derived the ‘reads_per_million_miRNA_mapped’ values for mature forms for each
miRNA from the ‘isoform_quantification’ files. For the miRNA-Seq data sets, the
following MIMAT numbers were analysed: MIMAT0000259 (hsa-miR-182-5p),
MIMAT0000222 (hsa-miR-192-5p), MIMAT0002868 (hsa-miR-522-3p),
MIMAT0018937 (hsa-miR-378g), MIMAT0003326 (hsa-miR-663a),
MIMAT0000258 (hsa-miR-181c-5p), MIMAT0000318 (hsa-miR-200b-3p),
MIMAT0000095 (hsa-miR-96-5p), MIMAT0014999 (hsa-miR-378b),
MIMAT0005870 (hsa-miR-1206), MIMAT0000266 (hsa-miR-205-5p),
MIMAT0000460 (hsa-miR-194-5p) and MIMAT0000440 (hsa-miR-191-5p).
The analyses were carried out in R statistical environment (version 3.0.1)
(http:///www.r-project.org/). All the tests were two-sided and considered
statistically significant at the 0.05 level. Clinical associations were used to prioritize
the 13 anti-angiogenic miRNAs for further investigation (Fig. 1). Kaplan–Meier
curves were plotted for all the data sets. For each miRNA, the tumour samples were
dichotomized into high and low miRNA expression groups at percentile cutoffs
between 0.25 and 0.75 with a step of 0.01. The optimal cutoff percentile
(as determined by the lowest P value) was identified for each miRNA. For each
miRNA, we tested whether a log-rank test applied at any cut-point would yield a
nominal P value o0.05; this flagged three miRNAs for further investigation.
For the miRNA-angiogenic factor correlation study, we examined the
expression levels of all the previously reported pro-angiogenic factors in the TCGA
ovarian data set (Agilent miRNA microarray and Agilent mRNA data sets were
used). The list of pro-angiogenic factors examined is presented in Supplementary
Data 2. We first checked and selected those pro-angiogenic genes that are
consistently expressed in TCGA samples. A ‘pro-angiogenic’ signature score was
subsequently computed for each TCGA sample using the formulae below
(equation (1))10:
Score ¼
XN
n¼1
geneexpr;n ð1Þ
Here, N is the number of genes in the list, the parameter geneexpr,n for a sample is 1
if the sample has a level of gene n above the median for all the TCGA samples and
 1 otherwise. The list of samples used for this analysis is presented in
Supplementary Table 6. The median expression of each angiogenic factor is
included in Supplementary Data 2. The correlation between the angiogenesis score
and miRNA expression was subsequently assessed for each miRNA for all the
samples (Spearman rank correlation). The contrasts between the angiogenic score
and component miRNA expression values were also used for filtering miRNAs for
follow-up; nominal P values for our best four miRNAs were o0.0001 (Fig. 1).
For the methylation analyses, we examined all the tumour tissue types in
TCGA that have methylation 450 data available. After eliminating the data
from replicate samples, we plotted miR-192 expression against the beta value for
each of the associated methylation probes (cg02258444-11-64658622, cg09349409-
11-64658765, cg18262830-11-64658819 and cg27083891-11-64658726). We
subsequently performed Spearman correlation analyses between miR-192
expression and the beta values for each probe.
Effect of miR-192 expression on mesenchymal phenotype. Agilent 244K
gene expression data and miRNA-seq expression data were obtained from the
open-access and controlled-access tiers of the TCGA data portal, with NIH
approval. The ovarian cancer tumour subtype information was obtained using a
previously established protocol14. The expression of miR-192 and TWIST1 were
compared between the mesenchymal and epithelial groups using the Wilcoxon
rank-sum test.
In vitro miRNA and siRNA transfection. The cells were transfected with 100 nM
of specified siRNAs using RNAiMax reagent (Invitrogen) at 3 ml reagent: 1 mg
siRNA ratio49. The cells were treated with siRNAs for 4 h in serum-free media
before incubation in fresh complete media for the specified time frame. All the
siRNA sequences are listed in Supplementary Table 7. For miRNA, reverse
transfection technique was used16. The cells were transfected with 40 nM miRNA
in media containing 10% FBS and the media were changed 4 h following
transfections to minimize toxicity. All the siRNAs were obtained from Sigma and
miRNAs were obtained from Life Technologies. MiRVana miRNA mimic negative
control #1 (catalogue number 4464061, ThermoFisher Scientific) was used as the
negative control.
Quantitative reverse transcription polymerase chain reaction. RNA was
isolated from the cells or tumours using Direct-zol RNA miniprep kit (Zymo
Research) according to the manufacturer’s protocol. cDNA was synthesized using a
Verso cDNA kit (Thermo Scientific) as per manufacturer’s instructions. Quanti-
tative reverse transcription PCR (RT–PCR) was performed on a 7500 Fast Real-
Time PCR System (Applied Biosystems)48. All primer sequences for mRNA
detection are listed in Supplementary Table 8. b-actin mRNA was used as the
normalizing control. For miRNA detection, Ambion assay probe sets (Life
technologies) were used according to the manufacturer’s protocol. RNU44 and
RNU6B were used as the normalizing control.
Cell apoptosis assay. Cell apoptosis assay was performed using the Annexin
V/propidium iodide (Invitrogen) staining kit according to the manufacturer’s
instructions. Cells were stained with fluorescein isothiocyanate-conjugated
Annexin V and propidium iodide for 30min and were analysed by flow cytometry
to determine the percentage of apoptotic cells.
Methylation-specific PCR. MethPrimer software (http://www.urogene.org/meth-
primer/) was used for design of methylation-specific primers for miR-192
(Supplementary Table 8). Total DNA was isolated from cells using the DNeasy blood
and tissue kit (Qiagen) as per the manufacturer’s protocol, followed by treatment
with bisulphite using a methylation kit (EZ DNA Methylation-Direct; Zymo
Research, Orange, CA). Using real-time PCR, as described above, quantification of
methylation was performed by comparing the ratios of unmethylated/methylated
levels in the control sample and the samples treated with 5-azacytidine (Sigma).
30-UTR assay. GoClone pLightSwitch IL-6, EGR1 and HOXB9 30-UTR luciferase
reporter constructs were obtained from SwitchGear genomics (Menlo Park, CA,
USA). For EGR1 and HOXB9, mutated constructs were also synthesized with the
predicted miR-192 binding sites deleted (Supplementary Fig. 2h). The SKOV3ip1
cells were transfected with FuGENE HD reagent in a 96-well plate with control
miRNA or miR-192 (40 nM) along with the 30-UTR reporter constructs, and
Cypridina TK control construct (pTK-Cluc) as per the manufacturer’s protocol50.
After 24 h of transfection, luciferase activity was obtained using LightSwitch Dual
Luciferase assay kits. All the assays were performed in quadruplicate.
Tumour cell
TWIST1
Pre-miR-192
miR-192
HOXB9 EGR1
Angiogenic
factors
Angiogenesis
MiR-192-DOPC
therapy
miR-
192
Figure 6 | Schematic representation of mechanisms by which miR-192
mediates its anti-angiogenic function. On the basis of findings described in
the manuscript, TWIST1 downregulates miR-192 levels in cancer cells,
leading to increased HOXB9 and EGR1 levels. These two transcription
factors, in turn, lead to increased levels of multiple pro-angiogenic factors
and increased tumour angiogenesis. Systemic delivery of miR-192 using
DOPC nanoliposomes represents a potent means of blocking tumour
angiogenesis and reducing tumour growth.
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Immunoblotting. Protein lysates were prepared from cultured cells using RIPA
buffer supplemented with protease and phosphatase inhibitors51. The protein
concentrations were determined using a BCA Protein Assay Reagent kit
(Pierce Biotechnology, Rockford, IL, USA). The lysates were loaded and separated
on 10% SDS–polyacrylamide gels. Nitrocellulose membranes were subsequently
probed with primary antibodies against EGR1 (1:1,000, Cell Signaling, Catalogue
number 4153), HOXB9 (1:1,000, Abcam, Catalogue number ab66765) and b-actin
(1:5,000, Sigma, Catalogue number A5316) in 5% BSA in TBS-T overnight at 4 C.
After washing with TBS-T, the membranes were incubated with horseradish
peroxidase (HRP)-conjugated secondary antibodies (1:2,000, GE Healthcare,
Catalogue numbers NA931 and NA934) for 2 h. HRP was visualized using an
enhanced chemiluminescence detection kit (PerkinElmer, Catalogue number
NEL104001EA). Full scans of important western blots are provided in
Supplementary Fig. 7.
ChIP assay. ChIP assays were performed using ChIP-IT Express Kit (Active
Motif) as per the manufacturer’s instructions. Briefly, crosslinked cells were
collected, lysed, sonicated and subjected to immunoprecipitation with TWIST1
(Abcam, Catalogue number Ab50887), EGR1 (Cell Signaling, Catalogue number
4153), HOXB9 (Abnova, Catalogue number H00003219-M05) or IgG isotype
control (Millipore, Catalogue number 12–371B for mouse IgG and Cell Signaling,
Catalogue number 2729, for rabbit IgG) antibodies. Immunocomplexes were
collected using protein A/G agarose magnetic beads and were eluted. PCR-based
quantification of fold enrichment in TWIST1, EGR1 or HOXB9 binding to miR-
192, IL6, EFNA1, IL1b or ITGA6 promoter regions was subsequently performed.
Liposomal nanoparticle preparation. MiRNA for in vivo delivery were
incorporated into DOPC liposomes49,52. DOPC and miRNA were mixed in the
presence of excess tertiary butanol at a ratio of 1:10 (w/w) miRNA/DOPC. Tween
20 was added to the mixture in a ratio of 1:19 Tween 20:miRNA/DOPC. The
mixture was then vortexed, frozen in an acetone/dry ice bath and lyophilized.
Before in vivo administration, this preparation was hydrated with PBS at room
temperature (5mg miRNA per 200 ml).
Orthotopic in vivo models of ovarian and renal cancer. Female athymic nude
mice (8–12 weeks old) were obtained from the National Cancer Institute, Frederick
Cancer Research and Development Center (Frederick, MD, USA). All the mouse
studies were approved and supervised by the M.D. Anderson Cancer Center Insti-
tutional Animal Care and Use Committee. For the therapeutic experiments, 10 mice
were assigned per treatment group. This sample size gave 80% power to detect a 50%
reduction in tumour weight with 95% confidence. To establish intraperitoneal
ovarian tumours, cells were injected into the peritoneal cavity (intraperitoneally) at a
concentration of 5–15 106 cellsml 1 (200ml per injection). For the renal cancer
model, renal cancer cells were injected into the renal subcapsular space in the right
kidney (0.3 million cells in 30ml HBSS). For therapeutic tumour growth inhibition
experiments, all the mice were treated with miRNA-DOPC (5mg, intraperitoneally)
twice a week beginning at 1 week following the tumour cell injection. For tumour
regression experiments, the mice received miRNA-DOPC treatments (5mg, intra-
peritoneally) twice a week starting on day 21 following the tumour cell injection.
Luciferase imaging was used to confirm tumour establishment before initiation of the
treatments16. Anti-VEGF B20–4.1.1 antibodies were administered intraperitoneally
twice a week (5mgkg 1, Genetech) and topotecan was administered intravenously
once a week (5mgkg 1, Sigma). The mice (n¼ 10 per group) were monitored for
adverse effects and the tumours were harvested after 3–4 weeks of therapy or when
any of the mice began to appear moribund. To examine the vessel permeability and
structure, three mice per treatment group received FITC-dextran (100ml,
10mgml 1, 2,000,000 MW; Sigma) before being killed. Ten minutes following the
dextran injection, the mice were perfused through the left ventricle with 4%
paraformaldehyde in PBS16. The mouse weight, tumour weight and the number/
location of tumour nodules were recorded. The tissues were fixed in 10% formalin or
embedded in Tissue-Tek optimal cutting temperature formulation for subsequent
sectioning16,49. For the survival experiment, mice bearing SKOV3ip1 tumours were
treated with control miRNA-DOPC or miR-192-DOPC twice a week starting at 1
week following the tumour cell injection. The mice were killed individually once they
became moribund. A Kaplan–Meier curve was used to analyse the survival difference
between control and treatment groups.
In vivo matrigel plug assay. After transfecting the SKOV3ip1 cells with either
control miRNA or miR-192 (40 nM), cells were exposed to serum-free media for
48 h. We then collected the supernatants and centrifuged them to remove cells. The
conditioned media were then mixed with phenol-red-free Matrigel (2:3 proportion,
total 0.5ml; BD Biosciences). The mixture was then injected into each mouse
subcutaneously (n¼ 3 per group)16. VEGF (0.25 nM, R & D Systems) was used as a
positive control. The mice were killed on day 8 and matrigel plug was examined for
haemoglobin content using the QuantiChrom hemoglobin assay kit as per the
manufacturer’s protocol (BioAssay Systems).
High-throughput miRNA profiling. Total RNA from human ovarian tumours was
extracted using mirVana RNA isolation labeling kit (Ambion) according to the
manufacturer’s protocol. RNA purity was assessed by a Nanodrop spectro-
photometric measurement (Thermo Scientific) of the OD260/280 ratio with
acceptable values falling between 1.9 and 2.1. RNA was diluted to 50mgml 1 using
RNase-free water and 3ml was used for miRNA profiling on the multiplexed
nCounter Human v2 miRNA platform (NanoString Technologies, Seattle, WA,
USA)53. RNA samples were prepared by ligating a specific DNA tag (miR-tag) onto
the 30 end of each mature miRNA as per the manufacturer’s instructions. Excess tags
were removed by restriction digestion at 37 C. Hybridizations were carried out by
combining 5ml of each miRNA-Tag sample with 20ml of nCounter Reporter probes
in hybridization buffer and 5ml of nCounter Capture probes at 65 C for 16–20 h.
Excess probes were removed using a two-step magnetic bead-based purification on
the nCounter Prep Station. Abundance of specific target molecules was quantified
using the nCounter Digital Analyzer by counting the individual fluorescent barcodes
and assessing target molecules. The data were collected using the nCounter Digital
Analyzer and were analysed using the nCounter Analysis system as per the
manufacturer’s instruction.
Microarray and pathway enrichment analyses. Microarray was performed on
Human HT-12 v4 Beadchip (Illumina) as per the manufacturer’s protocol50. The
SKOV3ip1 cells were treated with control miRNA or miR-192 (40 nM) using
RNAiMAX transfection reagent. Total RNA was extracted 48h following
transfection using mirVana RNA isolation labeling kit (Ambion). RNA purity was
assessed by a Nanodrop spectrophotometric measurement (Thermo Scientific) of the
OD260/280 ratio with acceptable values falling between 1.9 and 2.1. Five hundred
nanograms of total RNA were used for labelling and hybridization according to the
manufacturer’s protocols. After the bead chips were scanned with an Illumina
BeadArray Reader (Illumina, San Diego, CA, USA), the microarray data were
normalized using the quantile normalization method in the Linear Models for
Microarray Data package in the R language environment. The expression level of
each gene was transformed into a log2 base before further analysis. Ingenuity IPA
software was used to identify the genes that are most significantly downregulated
following the miR-192 treatment. The pathway enrichment analyses were performed
using NetWalker software16,54. Briefly, scoring of network components (nodes,
edges) for their relevance to a given data set is done by a random walk-based scoring
strategy by using the data values of nodes as transition probabilities. Each interaction
is assigned a probability value based on the data values of nodes in the
neighbourhood. Final relevance scores of nodes are given by their visitation
frequencies by the random walk at the end of infinite iterations.
Immunohistochemistry and immunofluorescence analyses. Staining was per-
formed in paraffin-embedded tumour sections as described previously16,49. For
patient samples, tissue microarray slides containing 128 ovarian cancer samples were
obtained from Wayne State University following approval by the Institutional
Review Board. All participants provided written informed consent. The three most
hypervascular areas in each tumour sample were selected for MVD assessment
(CD34 staining, 1:20, BioGenex Laboratories). The mean value for the three fields
was recorded and was expressed as the number of vessels per HPF ( 200). For
EGR1 and HOXB9 staining, antigen retrieval was performed using Borg Decloaker
solution (Biocare Medical). The slides were subsequently incubated with primary
antibodies against EGR1 (1:50, Cell Signaling, Catalogue number 4153) or HOXB9
(1:200, Abcam, Catalogue number ab66765) at 4 C overnight, followed by
incubation with DAKO EnVision Dual link system-HRP (Dako). The stained slides
were scored by two investigators blinded to patient survival information or miR-192
expression levels. A scoring system, which considered both the intensity of staining
and the percentage of cells stained, was used55,56. H scores of4100 andr100 were
defined as high and low expression, respectively. All the slides were counterstained
with Gill’s hematoloxylin #3.
For cleaved caspase-3 staining, formalin-fixed paraffin sections were
deparaffinized, and endogenous peroxide was blocked by incubating the slides with
3% hydrogen peroxide in PBS. The slides were incubated in 4% fish gelatin in PBS,
followed by an overnight incubation with the cleaved caspase-3 primary antibody
(1:100, Biocare Medical, Catalogue number CP229C). The slides were then
incubated with biotinylated goat anti-rabbit secondary antibody (Biocare Medical,
Catalogue number GR602H) for 20min, after which they were washed with PBS
and were later incubated with streptavidin HRP label (Biocare Medical, Catalogue
number HP604H) for 20min. All the slides were counterstained with Gill’s
hematoloxylin #3.
For CD31 and desmin staining, optimal cutting temperature embedded frozen
tissue sections of human or mouse tumours were used. The slides were incubated
with primary antibody for human CD31 (1:25, Dako, Catalogue number M0823),
mouse CD-31 (1:800, BD Pharmingen, Catalogue number 553370) and mouse
desmin (1:200, Abcam, Catalogue number ab15200) overnight at 4 C. For human
samples, two most hypervascular areas in each tumour sample were selected for
MVD assessment. The mean value for the two fields was recorded and was
expressed as the number of vessels per HPF ( 200). For in vivo samples, 5–10
random fields at  200 magnification for each tumour were examined. A vessel
was defined as an open lumen with at least one adjacent CD31-positive cell.
Multiple positive cells beside a single lumen were counted as one vessel. For
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pericyte coverage analysis, five random fields at  200 magnification were taken
per slide (five tumours per group), and the percentage of CD-31 staining blood
vessels with at least 50% pericyte coverage (positive desmin staining) were
enumerated per HPF. The quantification of extravascular FITC-dextran was
performed using the following scoring system16: 0 points, no staining; 1 point,
focal or o25%; 2 points, 25–50%; 3 points, 50–75%; and 4 points, 75–100%
FITC-dextran (use three fields per tumour at  400 magnification). For all the
immunofluorescent analyses, nuclear staining was performed with Hoechst 33342
(1:10,000, Molecular Probes).
MiRNA in situ hybridization. Tisue microarray samples for ovarian tumours were
used for miR-192 quantification. The formalin-fixed paraffin-embedded tissue sections
were dewaxed in xylenes, and rehydrated through an ethanol dilution series. The tissue
sections were digested with 15mgml 1 proteinase K for 20min at room temperature,
then loaded onto Ventana Discovery Ultra for in situ hybridization analysis16. The
tissue slides were incubated with double-DIG-labelled mercury LNA miR-192 probe
(Exiqon) for 2 h at 52 C. The double-DIG-labelled control U6 snRNA probe (Exiqon)
was used as a positive control. The digoxigenins were then detected with a polyclonal
anti-DIG antibody and alkaline phosphatase conjugated second antibody (Ventana)
using NBT-BCIP as the substrate. Representative light field images were obtained
using a Nikon Microphot-FXA microscope and Leica DFC320 digital camera. The
expression levels of miR-192 were determined using CellProfiler 2.0 software to
establish the staining intensity threshold levels and to quantify the number of
positively stained cancer cells per HPF ( 200 magnification)16.
Transcription factor analysis and target gene binding site prediction. Matbase
(Genomatix Inc.) was used to identify potential transcription factor-gene/miRNA
interactions. A matrix similarity score cutoff of 0.9 or 0.95 were used for identifying
transcription factors that can bind directly to the promoter regions of the
pro-angiogenic genes or miR-192, respectively. MiRwalk database57 was
subsequently used to identify transcription factors that can be directly targeted by
miR-192. The transcription factor–gene interaction was then plotted using
Cytoscape 3.2.1 software.
The putative miR-192 binding sites for a panel of transcription factors,
including EGR1 and HOXB9, were assessed bioinformatically using several
algorithms16. This was performed utilizing the following publically available sites:
http://www.microrna.org for the miRanda algorithm, http://www.targetscan.org
for the TargetScan algorithm, http://genie.weizmann.ac.il/pubs/mir07 for the
PITA algorithm, http://cbcsrv.watson.ibm.com for the RNA22 algorithm, http://
diana.cslab.ece.ntua.gr/microT for microT algorithm and http://genome.ucsc.edu/
cgi-bin/hgTables?command=start together with http://pictar.mdc-berlin.de/ for the
PicTar algorithm. We used Perl to retrieve and sort the information available
through these sources and Latex to present the miRNA binding sites most probable
to interact.
Generation of miR-192/EGR1/HOXB9 expressing cell lines. Stable lentiviral
miRNA vectors were purchased from Thermo Scientific (HMR5887 for non-tar-
geting control and V1SMHS_000952 for miR-192). The SKOV3ip1 cells were
transfected with each lentiviral vector and were selected with growth medium
containing puromycin according to the manufacturer’s protocol. To generate EGR1
and/or HOXB9 expressing cell lines, lentiviral vectors were generated from EGR1
(GE Healthcare) and HOXB9 vectors (Origene) lacking 30-UTR region. Following
viral transduction, the cells were selected or sorted using puromycin or GFP for
EGR1 and HOXB9, respectively.
Tube formation assays. The RF24 cells (2 104) were plated into each well in
Matrigel-coated 96-well plates (50ml per well, BD Biosciences)16. The cells were
incubated with conditioned media collected from stable SKOV3ip1 control miRNA
or miR-192 expressing cells or from ovarian or renal cancer cells treated control
miRNA, miR-192, miR-194 or miR-215 mimics. For the rescue experiments, IL-6
(8,000 pgml 1, R&D systems) and IL-8 (13,000 pgml 1, R&D systems) cytokines
were added to the conditioned media. Five wells were used per treatment group and
following 6 h of incubation, the images were taken using an Olympus IX81 inverted
microscope ( 100 or  200 magnification). The number of nodes (defined as when
at least three cells formed a single point) per image was quantified.
Endothelial cell extraction. After approval by the Institutional Review Board at
M.D. Anderson Cancer Center, three high-grade serous ovarian carcinomas and
three normal ovarian tissue samples were obtained immediately following the
resection. The endothelial cells were then extracted from tissues16. The samples
were treated with 5mM DTT and 10mM EDTA before being transferred to a small
dish where a few drops of digestion cocktail (Elastase 250 mgml 1, collagenase A
2mgml 1, DNAse 10 uml 1) were added. The tissues were then minced and
were further digested with collagenase A (1 gram tissue in 10ml) at 37 C for 1 h.
The cells were then spun down at 1,000 r.p.m. for 5min at room temperature and
were re-suspended in 10ml culture media (MEM medium, 15% FBS, 0.5%
gentomycin, 10 ngml 1 bFGF, 2mM L-glutamine, 1mM Na Pyruvate, 1 MEM
NEAA and vitamins). The cells were then loaded into Ficoll tubes and were pelleted
at 1,800 r.p.m. at room temperature for 20min. The 2–5ml interface layered cells
were collected, counted and re-suspended in a PBS/BSA buffer solution at 107
cellsml 1. The epithelial cells were removed by BerEP4 magnetic beads using a
magnet. Finally, a double-positive selection for endothelial cells was performed
using anti-CD31 and anti-CD146 antibodies by FACS sorting.
Statistical analysis. Statistical analysis for tumoral miR-192, EGR1 and HOXB9
expression in patients was performed as previously described55,56. Kaplan–Meier
survival curves were generated and compared with the use of a log-rank statistic to
assess the effect of tumoral miR-192, EGR1 or HOXB9 expression on overall survival.
The Spearman test was used to assess the correlation between miR-192 and gene
expression or angiogenic scores. For other assays, Student’s t-test was performed to
examine the difference between the control and treatment groups. A P value less than
0.05 was deemed statistically significant. All the statistical tests were two-sided.
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